NINDS Cooperative Program in Translational Research Multi Component Research Projects (U54) | Apply Online

Frequently Asked Questions (FAQs)

What is the NINDS Cooperative Program in Translational Research Multi Component Research Projects (U54)?

This is a National Institutes of Health (NIH) funding opportunity from the National Institute of Neurological Disorders and Stroke (NINDS) designed to move promising neurological therapies through the final major phase of preclinical development so they are positioned to enter human testing.

What is the main goal of this funding opportunity?

The main goal is to accelerate translation by supporting development-focused work on a therapy-directed lead that already shows demonstrated activity against the intended disease target, with the expectation that the project can reach an FDA regulatory submission (IND or IDE) by the end of the award period.

What stage of research is this program meant to support?

The program is aimed at teams that are beyond early discovery and are ready for rigorous preclinical optimization, validation, and testing needed to produce a realistic therapeutic candidate.

What does NINDS mean by a "therapy-directed lead" that is ready for this program?

Based on the announcement description, the lead should already be identified and should have demonstrated activity against the intended disease target. The remaining work should focus on development steps needed to optimize and validate the candidate for regulatory submission, rather than exploratory discovery.

What are the expected outcomes by the end of the award?

Supported projects are expected to be advanced enough that, by the end of the award period, they can submit either an Investigational New Drug (IND) application or an Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA).

What kinds of preclinical activities are expected to be included in an application?

The opportunity emphasizes a coherent development plan that addresses studies regulators typically require. Examples mentioned include dose and formulation work, pharmacology, safety assessments, and other preclinical packages appropriate to the modality (drug, biologic, or device) and the intended indication.

Is this program focused on basic science or mechanism-of-disease research?

No. The program is centered on preclinical development and testing to advance a therapy toward regulatory submission, rather than generating new basic insights or focusing primarily on disease mechanisms.

What activities are explicitly not funded under this opportunity?

The description states that the program explicitly excludes early-stage therapeutic discovery activities (such as high-throughput screening). It also does not support clinical research, basic research, or studies primarily focused on disease mechanisms.

Does this program support clinical research or human testing?

No. The program is designed to position therapies for entry into human testing, but it does not support clinical research itself.

What does "U54 Specialized Center Cooperative Agreement" mean for applicants?

The U54 mechanism is a cooperative, milestone-driven structure rather than a hands-off grant. NINDS staff are expected to participate in developing the project plan and monitoring progress over time.

How involved is NINDS during the project under this cooperative agreement?

The structure anticipates active program involvement, with the work organized around clear milestones and go/no-go decision points. NINDS staff participation is intended to help keep projects aligned with translational objectives and on track for the IND/IDE goal.

Why does the opportunity emphasize milestones and go/no-go decision points?

As described, the milestone and decision-point approach is meant to improve accountability and speed by emphasizing measurable progress and enabling timely course correction so the preclinical package stays on track for regulatory submission.

Are the funding amount, project size, or project duration fixed?

No. The FOA notes that the size and duration of awards will vary depending on the scope of each application, and the total number of awards depends on the quality, timeframe, and cost of the proposals received.

Is cost sharing or matching required?

No cost sharing or matching requirement is listed in the information provided.

Who is eligible to apply?

Eligibility is broad and includes public and private institutions of higher education; nonprofit organizations (501(c)(3) and non-501(c)(3)); for-profit organizations (including small businesses); state and local governments; independent school districts; public housing authorities/Indian housing authorities; Native American tribal governments (federally recognized and others); HBCUs; Hispanic-serving institutions; tribally controlled colleges and universities; Alaska Native and Native Hawaiian serving institutions; regional organizations; U.S. territories or possessions; eligible federal agencies; and faith-based and community-based organizations.

Can for-profit organizations and small businesses apply?

Yes. For-profit organizations, including small businesses and other for-profits, are included in the eligibility list provided.

Can government entities apply?

Yes. State and local governments (including county, city or township, and special district governments), as well as eligible federal agencies, are included as eligible applicants.

Can tribal governments and tribal institutions apply?

Yes. The eligibility list includes Native American tribal governments (federally recognized and other than federally recognized) and tribally controlled colleges and universities.

What kinds of therapy modalities does this program cover?

The description indicates projects may involve modalities such as drugs, biologics, or devices, with preclinical development packages tailored to the modality and indication.

What is the funding opportunity identifier for this program?

The opportunity is identified as PAR-08-234.

What is the CFDA number associated with this opportunity?

The CFDA number listed is 93.853, titled "Extramural Research Programs in the Neurosciences and Neurological Disorders."

Which agency and institute sponsor this opportunity?

The sponsoring agency is the National Institutes of Health (NIH), and the relevant institute for this neurological disorder-focused program is NINDS.

When was this opportunity posted and when did it close?

It was posted on December 3, 2008. The original and final closing date was September 7, 2011, and the archive date was October 8, 2011.

Where was the full announcement made available?

The full announcement was made available through NIH's grants guide, and NIH's Office of Extramural Research provided contact support for access or linking issues.